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Kappa opioid receptor (KOPr) agonists represent alternative analgesics for their low abuse
potential, although relevant adverse effects have limited their clinical use. Functionally
selective KOPr agonists may activate, in a pathway-specific manner, G protein-mediated
signaling, that produces antinociception, over b-arrestin 2-dependent induction of
p38MAPK, which preferentially contributes to adverse effects. Thus, functionally
selective KOPr agonists biased toward G protein-coupled intracellular signaling over b-
arrestin-2-mediated pathways may be considered candidate therapeutics possibly devoid
of many of the typical adverse effects elicited by classic KOPr agonists. Nonetheless, the
potential utility of functionally selective agonists at opioid receptors is still highly debated;
therefore, further studies are necessary to fully understand whether it will be possible to
develop more effective and safer analgesics by exploiting functional selectivity at KOPr. In
the present study we investigated in vitro functional selectivity and in vivo antinociceptive
effects of LOR17, a novel KOPr selective peptidic agonist that we synthesized. LOR17-
mediated effects on adenylyl cyclase inhibition, ERK1/2, p38MAPK phosphorylation, and
astrocyte cell proliferation were studied in HEK-293 cells expressing hKOPr, U87-MG
glioblastoma cells, and primary human astrocytes; biased agonism was investigated via
cAMP ELISA and b-arrestin 2 recruitment assays. Antinociception and antihypersensitivity
were assessed in mice via warm-water tail-withdrawal test, intraperitoneal acid-induced
writhing, and a model of oxaliplatin-induced neuropathic cold hypersensitivity. Effects of
LOR17 on locomotor activity, exploratory activity, and forced-swim behavior were also
assayed. We found that LOR17 is a selective, G protein biased KOPr agonist that inhibits
adenylyl cyclase and activates early-phase ERK1/2 phosphorylation. Conversely to classic
KOPr agonists as U50,488, LOR17 neither induces p38MAPK phosphorylation nor
increases KOPr-dependent, p38MAPK-mediated cell proliferation in astrocytes.
Moreover, LOR17 counteracts, in a concentration-dependent manner, U50,488-
induced p38MAPK phosphorylation and astrocyte cell proliferation. Both U50,488 and
LOR17 display potent antinociception in models of acute nociception, whereas LOR17in.org March 2020 | Volume 11 | Article 1881
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Frontiers in Pharmacology | www.frontiersincounteracts oxaliplatin-induced thermal hypersensitivity better than U50,488, and it is
effective after single or repeated s.c. administration. LOR17 administered at a dose that
fully alleviated oxaliplatin-induced thermal hypersensitivity did not alter motor
coordination, locomotor and exploratory activities nor induced pro-depressant-like
behavior. LOR17, therefore, may emerge as a novel KOPr agonist displaying functional
selectivity toward G protein signaling and eliciting antinociceptive/antihypersensitivity
effects in different animal models, including oxaliplatin-induced neuropathy.Keywords: kappa opioid receptor, functional selectivity, intracellular signaling, chemotherapy-induced
neuropathic pain, antinociceptionINTRODUCTION
Mu opioid receptor (MOPr) agonists, such as morphine,
oxycodone and fentanyl, are still among the most potent and
widely used analgesics; nonetheless, their high addictive potential
and relevant adverse effects may significantly limit their clinical
utility, thus highlighting the need for more effective and safer
pain killers (Yekkirala et al., 2017). Kappa opioid receptor
(KOPr) agonists have been intensively investigated in the last
decade as alternatives to MOPr analgesics due to their low abuse
potential and minimal adverse effects on gastrointestinal transit
and respiration (Lemos and Chavkin, 2011). KOPr activation by
agonists induces antinociception and may also prevent
hyperalgesia produced by chronic use of MOPr targeting
therapeutics (Kivell and Prisinzano, 2010; Vanderah, 2010).
However, the clinical use of currently available KOPr agonists
is limited by their relevant side effects, such as severe dysphoria,
neuropathy-induced astrocyte proliferation and subsequent
hyperalgesia, sedation, coordination impairment, and
anhedonia (Bruchas and Chavkin, 2010; Bruchas and Roth,
2016). Indeed, no KOPr agonist is presently used to treat pain
in humans (Bedini and Spampinato, 2018).
Functional selectivity (also called ligand-directed signaling or
biased agonism) - namely, the ability of a ligand at a GPCR to
selectively activate specific cell signaling pathways over others -
represents an intriguing opportunity in pharmacological
research, as some transduction pathways may be related to
therapeutic responses, whereas others may be connected to
adverse effects of a drug (Urban et al., 2007; Kenakin and
Christopoulos, 2013).
In this regard, an accumulating body of evidence suggests that
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.org 2G protein-mediated signaling (Bruchas and Chavkin, 2010;
Morgenweck et al., 2015) while their b-arrestin-2-dependent
induction of p38MAPK leads to many of the relevant adverse
consequences, including centrally mediated dysphoria (Bruchas
et al., 2007; Ehrich et al., 2015), potassium channel heterologous
desensitization (Clayton et al., 2009), neuropathy-induced
astrocyte proliferation and related hyperalgesia (Xu et al.,
2007), sedation, and motor incoordination (Dunn et al., 2018).
Thus, functionally selective KOPr agonists biased toward G
protein-coupled intracellular signaling over b-arrestin-2-
mediated pathways may be considered candidate therapeutics
possibly devoid of the above-described adverse effects (Bruchas
and Roth, 2016).
As regard functional selective opioid ligands it is important to
remind that in October 2018, the US FDA did not approve the G-
protein biased MOPr agonist oliceridine, as it was found not
safer than morphine (Azzam et al., 2019); nonetheless, great
interest in developing biased ligands at other GPCRs as KOPr
still remains (Conibear and Kelly, 2019), and future studies
analyzing novel compounds and correlating the degree of
signaling bias to specific pharmacological responses are
considered greatly beneficial for the whole kappa field (Mores
et al., 2019).
Within this frame, by synthesizing and characterizing a series
of peptide hybrids of the cyclic tetrapeptide c[Phe-D-Pro-Phe-
Trp] (CJ-15,208) and the cyclic pentapeptide c[Tyr-D-Pro- D-
Trp-Phe- Gly] (Cyclo EM-1) (De Marco et al., 2016), we
identified a new KOPr ligand, LOR17 (c[Phe-Gly-(b-Ala)-D-
Trp]); here, we describe its synthesis as well as in vitro and in vivo
pharmacological characterization, with the purpose of
ascertaining whether LOR17 may act as a functionally selective
KOPr agonist: to do so, we investigated LOR17-mediated
modulation of G protein- or b-arrestin-2-, p38MAPK-
dependent signaling pathways and related cellular responses in
vitro, as well as its in vivo activity in mouse models of nociceptive
and neuropathic pain, by comparing its effects to those elicited by
the classic KOPr reference agonist U50,488. Accordingly, in
addition to determining LOR17 affinity and selectivity to
KOPr, we employed different cell models to study LOR17-
mediated effects on adenylyl cyclase inhibition (a G protein-
dependent event), ERK1/2 and p38MAPK phosphorylation, and
astrocyte cell proliferation (a p38MAPK-dependent event). With
regard to this latter cellular response, it is relevant to be remindedMarch 2020 | Volume 11 | Article 188
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dynorphin is released and promotes KOPr-dependent, b-arrestin
2-, and p38MAPK-mediated astrocytes activation and
proliferation; thus leading to allodynia and hyperalgesia
(Jolivalt et al., 2006; Xu et al., 2007; Aita et al., 2010). Given
that also drug efficacy, and not only signaling bias, could
determine differential pharmacological profiles (Conibear and
Kelly, 2019), we investigated LOR17 ability to counteract
U50,488-mediated increase in p38MAPK phosphorylation and
the subsequent astrocytes proliferation.
cAMP ELISA and b-arrestin-2 recruitment assay were
employed to characterize biased agonism; moreover, ligands’
ability to recruit b-arrestin-2 at KOPr was assessed also by means
of a BRET-based assay carried out in HEK-293 cells. U50,488
was also tested in all the experimental settings listed above.
Furthermore, we compared LOR17 and U50,488 efficacy in
producing antinociception in the warm-water tail-withdrawal
test and in the writhing test in mice, as well as their effectiveness
in counteracting thermal hypersensitivity in a mouse model of
oxaliplatin-induced neuropathic pain. Finally, we assessed the
effects elicited by LOR17 on motor coordination, locomotor and
exploratory activities, and pro-depressant-like behavior.MATERIALS AND METHODS
General Procedure for the Synthesis of
Cyclic Peptides
Standard chemicals were obtained from Sigma Aldrich. The
synthesis was performed using a MicroSYNTH microwave lab
station equipped with a built-in ATC-FO advanced fiber optic
automatic temperature control. Purities were determined to be
>95% by analytical reversed-phase (RP)-HPLC, performed on an
Agilent 1100 series apparatus, using an RP column Phenomenex
mod. Gemini 3m C18 110 Å 100×3×3.0 mm (P/No 00D-4439-
Y0); stationary phase: octadecyl carbon chain-bonded silica
(C18) with TMS end-capping, fully porous organo-silica solid
support, particle size 3 mm, pore size 110 Å, length 100 mm,
internal diameter 3 mm; DAD 210 nm; mobile phase: from 9:1
H2O/CH3CN to 2:8 H2O/CH3CN in 20 min, flow rate 1.0 ml
min, then 10 min at the same composition. Semi-preparative RP-
HPLC was performed on an Agilent 1100 series apparatus using
an RP column ZORBAX mod. Eclipse XDBC18 PrepHT
cartridge 21.2×3×150 mm 7m (P/No 977150-102); stationary
phase: octadecyl carbon chain-bonded silica (C18), double
end-capped, particle size 7 µm, pore size 80 Å, length 150 mm,
internal diameter 21.2 mm; DAD 210 nm; mobile phase: from
8:2 H2O-CH3CN to 100% CH3CN in 10 min, at a flow rate of
12 ml min. ESI analysis was performed using an MS single
quadrupole HP 1100MSD detector with a drying gas flow of 12.5
L/min, nebulizer pressure 30 psgi, drying gas temp. 350°C,
capillary voltage 4,500 (1) and 4,000 (2), and scan range 50–
2,600 amu.
Synthesis of LOR17
The linear peptide was assembled by MW-assisted SPPS on a
commercially available Wang resin preloaded with Fmoc-PheFrontiers in Pharmacology | www.frontiersin.org 3using Fmoc-protected amino acids and TBTU/HOBt/DIPEA as
coupling agents. All steps were performed according to the
following general procedures.
Fmoc deprotection: The Fmoc-Phe-Wang resin (0.5 g, Phe
loading 0.4–0.8 mmol/g) was treated with 20% piperidine in DMF
(5 ml) for 2 min under MW irradiation at 40 W, maintaining the
internal temperature at 45°C. The resin was filtered and washed
with DCM (5ml), and the treatment with 20% piperidine in DMF
was repeated as described above. The suspension was then
filtered, and the resin was washed three times in sequence with
DCM (5 ml), MeOH (5 ml), and DMF (5 ml).
Peptide bond formation: The resin was swollen in DCM (5
ml), and a mixture of Fmoc-amino acid (0.6 mmol) and the
coupling reagents TBTU/HOBt/DIPEA were added under a
nitrogen atmosphere to the resin. The suspension was heated
while bubbling N2 by MW irradiation. After 10 min, the resin
was washed 3 times with DMF (5 ml) and MeOH (5 ml), and
coupling efficacy was determined by the Kaiser test. The
subsequent deprotec t ion steps were performed as
reported above.
Peptide cleavage: The resin was treated with a mixture of TFA
and TIPS/water/PhOH as scavengers (7:1:1:1 v/v, 15 ml) for 2 h
at r.t. After this time, the resin was filtered, and it was washed 3
times with 5% TFA in Et2O (10 ml). The filtrate and the washes
were collected and removed at r.t. under N2 flow. The oily
residue was suspended in ice-cold Et2O, and the precipitate was
collected by centrifugation. The purity of the product was
determined to be approximately 85% by RP HPLC (see
General Procedure)
Cyclization: The linear peptide (0.1 mmol) in DMF (5 ml) was
added over 12 h using a KD Scientific single infusion syringe
pump and a 10 ml syringe to a stirred solution of HATU (0.4
mmol) and DIPEA (1.0 mmol) in DMF (20 ml). The reaction
was stirred for an additional 12 h. The solvent was distilled under
high vacuum, and the residue was dissolved in EtOAc (40 ml)
and washed twice with 1 N citric acid (5 ml), saturated
bicarbonate (5 ml) and brine (5 ml). The organic layer was
dried over Na2SO4, and the solvent was removed under reduced
pressure. The resulting crude residues were purified by semi-
preparative RP HPLC (see General Procedure), and the cyclic
peptides were characterized by reversed-phase HPLC,
electrospray ionization mass spectrometry, and 1H and 13C
NMR. Purities were determined to be >95% by analytical RP-
HPLC and elemental analysis (see General Procedure).
1H NMR b c[Phe-Gly-b-Ala-D-Trp]1H NMR (400 MHz,
[D6]DMSO) d: 2.12 (m, 1H, b-AlaHa), 2.32 (m, 1H, b-AlaHa),
2.78 (dd, J = 5.2, 13.7 Hz, 1H, PheHb), 2.82 (dd, J = 6.8, 14.4 Hz,
1H, D-TrpHb), 3.02 (dd, J = 6.6, 13.7 Hz, 1H, PheHb), 3.10 (dd,
J = 8.0, 14.4 Hz, 1H, D-TrpHb), 3.18 (m, 1H, b-AlaHb), 3.30 (dd,
J = 4.4, 15.0 Hz, 1H, GlyHa), 3.46 (m, 1H, b-AlaHb), 3.90 (dd, J =
6.4, 15.0 Hz, 1H, GlyHa), 4.51 (ddd, J = 5.2, 6.6, 8.8 Hz, 1H,
PheHa), 4.65 (ddd, J = 6.8, 8.0, 8.4 Hz, 1H, D-TrpHa), 6.71 (br.t,
1H, b-AlaNH), 6.90-6.98 (m, 2H, D-TrpArH2,5), 7.05 (dd, J =
6.8, 7.6 Hz, 1H, D-TrpArH6), 7.10-7.18 (m, 3H, PheArH2,4,6),
7.19-7.22 (m, 2H, PheArH3,5), 7.32 (d, J = 7.6 Hz, 1H, D-
TrpArH7), 7.49 (d, J = 7.6 Hz, 1H, D-TrpArH4), 8.00 (br.t, 1H,
GlyNH), 8.31 (d, J = 8.8 Hz, 1H, PheNH), 8.50 (d, J = 8.4 Hz, 1H,March 2020 | Volume 11 | Article 188
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[D6]DMSO) d: 26.5, 36.3, 36.6, 40.1, 44.6, 54.1, 55.2, 111.2, 112.5,
119.3, 119.4, 122.1, 124.1, 127.4, 128.3, 129.3, 137.3, 170.2, 172.0,
172.1, 172.7. ES-MS m/z [M+1] found: 462.2, calculated: 462.5.
Elementary analysis for C25H27N5O4 calculated: C 65.06, H
5.90, N 15.17, found: C 65.26, H 6.00, N 15.01
Cell Culture
HEK-293 cells (ATCC, Rockville, MD, USA, passages 25-35) stably
expressing hMOPr (HEK-293/hMOPr), human delta opioid
receptor (hDOPr) (HEK-293/hDOPr), or hKOPr (HEK-293/
hKOPr) were obtained as previously reported (De Marco et al.,
2012). HEK-293/hMOPr, HEK-293/hDOPr, HEK-293/hKOPr, and
U87-MG human astrocytoma cells (ATCC, passages 3–15) were
grown as monolayers in minimal essential medium (Lonza Group
Ltd, Basel, Switzerland) supplemented with 2 mM L-Glutamine
(Lonza), 1x non-essential amino acids (Life Technologies, Monza,
Italy) and 1x antibiotic-antimycotic solution (Life Technologies),
containing 10% fetal bovine serum (Life Technologies), and cultured
at 37°C in a humidified atmosphere of 5% CO2.
Primary cultures of human astrocytes were obtained from
Lonza (CloneticsTM Astrocyte Cell Systems, Lonza,
Walkersville, MD USA), grown as a monolayer in astrocyte
basal medium (ABM) supplemented with 2 mM L-Glutamine,
0.1% rhEGF, 0.25% insulin, 0.1% ascorbic acid, 0.1% GA-1000,
3% FBS and cultured at 37°C in a humidified atmosphere of 5%
CO2. Human astrocytes were used in the range of passages 1–9.
Radioligand Binding Assay
To determine KOPr protein expression levels in HEK-293/
hKOR, U87-MG and normal human astrocytes, saturation
binding assays were performed as follows: cell membranes
were prepared as previously described (Bedini et al., 2017), and
protein concentration was determined by the BCA assay kit
(Thermo Fisher). For saturation binding experiments, cell
membranes (40 mg) were incubated in 100 mM Tris–HCl, pH
7.4, containing 0.3% bovine serum albumin with increasing
concentrations of [3H]U69,593 (20 pM - 5 nM) (PerkinElmer,
Milan, Italy). Non-specific binding was determined in the
presence of U50,488 (10 mM). After 90 min incubation at 25°
C, bound ligand was isolated by rapid filtration onWhatman GF/
C filters (Schleicher & Schuell, Dassel, Germany). Filters were
washed with 20 ml of ice-cold 50 mM Tris–HCl buffer, pH 7.4,
and left in scintillation fluid overnight before counting.
GraphPad Prism software (GraphPad Software Inc., San Diego,
CA, USA) was used to calculate receptor density (Bmax) and
dissociation equilibrium constant (Kd). Data are expressed as
fmol of [3H]U69,593 bound and normalized to cell homogenate
protein content.
To evaluate affinity of LOR17 to the opioid receptors,
displacement binding assays were performed in HEK-293/
hMOPr, HEK-293/hDOPr, and HEK-293/hKOPr using [3H]
DAMGO, [3H]diprenorphine, or [3H]U69,593 as MOPr-,
DOPr- and KOPr-specific radioligands, respectively. DAMGO,
DPDPE, and U50,488 were employed as reference MOPr, DOPr,
and KOPr ligands, respectively. Cell membranes from MOPr-,
DOPr-, and KOPr-expressing HEK-293 cells were prepared asFrontiers in Pharmacology | www.frontiersin.org 4previously reported (De Marco et al., 2016). Membrane
preparations were incubated with 2.5 nM [3H]DAMGO, 2 nM
[3H]-diprenorphine, or 1 nM [3H]U69,593 at 25°C for 90 min in
buffer containing 100 mM Tris-HCl and 0.3% BSA in the
presence or absence of LOR17 at various concentrations (10-
12-10-4 M). Triplicate determinations were made for each
experiment. Reactions were terminated by filtration through
Whatman GF/C filters presoaked with 0.3% polyethylenimine,
which were washed three times with 5 ml of ice-cold buffer
containing 50 mM Tris-HCl, pH 7.4. The radioactivity trapped
was determined by liquid scintillation spectrometry. Data from
at least five independent experiments were fitted by nonlinear
regression analysis using GraphPad Prism. Ki values were
calculated from the IC50 using the Cheng-Prusoff equation.
Inhibition of cAMP Accumulation by
LOR17 and U50,488
The activity of LOR and U50,488 was determined by measuring
the inhibition of forskolin-stimulated cAMP accumulation in
whole HEK-293/hKOPr cells, U87-MG cells and normal human
astrocytes. Samples in a 75 cm2 flask at 95–100% confluence were
split into 24 wells and incubated overnight. When the confluence
became 85–95%, the medium was removed and the cells were
washed three times with PBS; thereafter, cells were incubated in
serum-free medium containing 0.5 mM 3-isobutyl-1-
methylxanthine and exposed for 15 min to 10 mM forskolin,
without and with each compound (0.001 nM to 100 mM) at 37°C.
Cells were then lysed in 0.1 N HCl, scraped off, and centrifuged
(2,000 g, 5 min). Supernatants were assayed for cAMP
concentration using a cAMP EIA kit (Cayman Chemicals, Ann
Arbor MI, USA) according to the manufacturer’s instructions.
b-Arrestin 2 Recruitment
b-arrestin 2 recruitment at KOPr was investigated by using the
DiscoveRxPathHunter® eXpressb-arrestin2 assay (Eurofins-
DiscoveRx, CA, USA) according to manufacturer ’s
recommendations and previously published procedures (Zhou et
al., 2013; Spetea et al., 2017). Briefly, U2OS cells provided with the
kit and stably co-expressing the kappa receptor and the enzyme
acceptor-tagged b-arrestin2 fusion protein were seeded in cell
plating medium into 96-well plates (10,000 cells per well) and
maintained for 48 h at 37°C. Cells were then exposed to vehicle,
LOR17 (0–10 mM) or U50,488 (0–10 mM) and incubated for 3 h at
37°C; after that the detection mix was added and incubation was
continued for further 60 min at room temperature in the dark.
Chemiluminescence was measured via EnSpire® Multimode Plate
Reader (PerkinElmer Inc.,Milan, Italy).All compoundswere run in
parallel assays in duplicate for comparison.
BRET Assay
BRET-based assay with mYFP as the acceptor and RLuc as the
donor was employed to investigate b-arrestin 2 recruitment at
KOPr in HEK-293 cells exposed to vehicle, LOR17 (1–10 mM) or
U50,488 (1–10 mM). BRET assay was carried out as previously
reported (Gimenez et al., 2012; Bedini, 2015): briefly, HEK-293
cells were seeded into 6-well multiplates and transfected, using
Lipofectamine® 2,000 (Invitrogen) according to theMarch 2020 | Volume 11 | Article 188
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each mg of DNA), with increasing amounts of mYFP-b-arrestin 2
constructs (0–12 mg) along with 250 ng of KOPr-Luc encoding
plasmid and empty pcDNA3 to equalize DNA amount. The day
after transfection, cells were detached and plated into 96-well
multiplates as previously described (Bedini, 2015). After 24 h
cells were treated with vehicle, LOR17 (1–10 mM) or U50,488 (1–
10 mM); then 5 mM coelenterazine-h was added and fluorescence
and luminescence signals were detected via EnSpire® Multimode
Plate Reader (PerkinElmer Inc., Milan, Italy) at different time
points between 5 and 60 min after ligands administration,
according to the protocol previously reported (Bedini, 2015).
The net BRET ratio was calculated as the long wavelength
emission divided by the short wavelength emission and
expressed as the relative change compared with unstimulated
cells. The expression of mYFP-b-arrestin 2 was evaluated using
fluorescence at 535 nm upon excitation at 485 nm. The mYFP-b-
arrestin 2 fluorescence, which is directly proportional to the
expression levels, was normalized by the basal luminescence
from the respective KOPr-RLuc construct (F/L ratio) to account
for variations in cell number and expression levels.
Small Interfering RNA
b-arrestin-2 expression in U87-MG cells was knocked-down via
a selective small interfering RNA (siRNA) as previously reported
(Bedini et al., 2017). Briefly, siRNA for b-arrestin-2 or negative
control siRNA (ctrl siRNA) were Silencer® select pre-designed
and validated siRNA obtained from Thermo Fisher Scientific
(Walthman. Ma, USA). U87 cells were transfected with b-
arrest in-2 siRNA or ctrl s iRNA (50 nM) by using
Lipofectamine® RNAiMAX (Thermo Fisher Scientific)
according to the manufacturer’s protocol and treatments were
started 48 h later. The effectiveness of b-arrestin-2 silencing via
siRNA was confirmed by western blot by using an anti-b-
arrestin-2 antibody purchased from Abcam, according to the
procedure that we previously employed (Bedini et al., 2017).
Western Blot Analysis
HEK-293 cells stably expressing KOPr, U87-MG astrocytoma cells,
or normal human astrocytes endogenously expressing KOPr were
plated into 6-well plates until 60–70% confluencewas reached. Then,
the cells were serum-starved for 16–18 h and subsequently exposed
to vehicle, LOR17 (1 mM; 0–120 min) or U50,488 (1 mM; 0–120
min). Alternatively, HEK-295/hKOPr and U87-MG cells were
exposed to norBNI (10 mM; 30 min prior to LOR17) and then
treated with 1 mM LOR17, or they were exposed to increasing
concentration of LOR17 (1–100 mM; 30 min). Proteins were
extracted as previously reported (Kuhar et al., 2015), quantified by
means of BCA assay (Pierce) and SDS-page gel electrophoresis
performed as previously described for ERK1/2 (Baiula et al., 2016)
and p38MAPK (Schattauer et al., 2012).
Membranes were then incubated with anti-phospho-ERK 1/2
(1:1,000) (Cell Signaling Technology, Danvers, MA, USA), anti-
total ERK1/2 antibodies (1:1,000) (Cell Signaling Technology),
anti-phospho-p38MAPK antibodies (1:1,000) (Cell Signaling
Technology, Danvers, MA, USA), or anti-actin antibodies
(1:2,500) (Santa Cruz Biotechnology, Dallas, TX, USA) at 4°CFrontiers in Pharmacology | www.frontiersin.org 5in the presence of BSA (5 g/100 ml) in Tris buffered saline
containing Tween-20 (0.1 g/100 ml). After washing, anti-rabbit
horseradish peroxidase-conjugated secondary antibodies (Santa
Cruz Biotechnology, Dallas, TX, USA) were added to membranes
for 1.5 h at room temperature. The protocol of image acquisition
and analysis has been previously described (Bedini et al., 2008)
All the raw images of each representative western blot are
included in the Data Sheet 1.
Cell Proliferation Assay
A cell proliferation assay was carried out as previously reported
(Bedini et al., 2017). Briefly, U87-MG cells or normal human
astrocytes were plated on a 12-well plate and treated as described
in the results section or maintained in cell culture medium
containing 10% fetal bovine serum. Five hours before the end of
the treatments, [methyl-3H] thymidine (PerkinElmer) (50nMfinal
concentration) was added to serum-free cell culture medium, and
the plate was incubated at 37°C. Thereafter, the medium was
removed, and the cells were washed twice with PBS. Then, 200 ml
of PBS was added to each well, and the cells were scraped off and
centrifuged at 13,000 g for 3min at 4°C.The supernatantswere then
discarded, pellets were re-suspended in 500 ml of cold
trichloroacetic acid (10% w/v), incubated on ice for 20 min and
centrifuged at 13,000 g for 3 min at 4°C. The supernatant was then
discarded, and the pellet was suspended in 500 ml of coldmethanol
and centrifuged at 3 min for 13,000 g at 4°C. Thereafter, the pellet
was suspended in 200 ml of 1 N NaOH and heated at 55°C for 10
min. Samples were then neutralizedwith 200ml of 1NHCl and 350
ml of the labelled DNA incubated in counting vials with 4 ml of
Filter Count scintillation liquid (Perkin Elmer Italia). Vials were
vortexed and incubated overnight at room temperature, and the
radioactivity was determined by liquid scintillation spectrometry.
Animals
CD-1 adult male mice (23–25 g) were used in the experiments.
The animals were fed a standard laboratory diet and tap water ad
libitum and housed in a room kept at 23 ± 1°C with a 12 h light/
dark cycle (light on at 7 a.m.). All animal manipulations were
carried out according to the Directive 2010/63/EU of the
European parliament and of the European Union council (22
September 2010) on the protection of animals used for scientific
purposes. The procedures regarding the warm-water tail-
withdrawal test and writhing test employed in this study were
approved by the Animal Care and Use Committee of the
University of Bologna (Prot. n. 29-IX/9, 25th July 2012) and
conformed to the International Association for the Study of Pain
(IASP) guidelines on ethical standards for the investigation of
experimental pain in animals. The ethical policy of the
University of Florence complies with the Guide for the Care
and Use of Laboratory Animals of the US National Institutes of
Health (NIH Publication No. 85-23, revised 1996; University of
Florence assurance number: A5278-01). Formal approval to
conduct the experiments in the mouse model of oxaliplatin-
induced neuropathy, rotarod test, hole-board test and forced
swimming test was obtained from the Animal Subjects Review
Board of the University of Florence. Experiments involving
animals have been reported according to ARRIVE guidelinesMarch 2020 | Volume 11 | Article 188
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animal suffering and to reduce the number of animals used.
Warm-Water Tail-Withdrawal Test
The warm-water tail-withdrawal test was performed as
previously described (Bedini et al., 2010). Briefly, a mouse’s tail
was immersed in hot water (52 ± 0.5°C), and the latency to tail
withdrawal was measured as an indicator of nociception. Prior to
being treated, each mouse was tested, and the latency to tail
withdrawal was recorded (control latency, CL). Animals not
withdrawing their tails within 5 s were not used (6% of mice).
Responding animals were then injected i.p. with either vehicle or
one of the compounds (LOR17 or U50,488; 0–20 mg/kg). The
KOR antagonist norBNI (10 mg/kg; i.p.) was injected 30 min or
24 h prior to administering LOR17.
Latency to withdrawal was measured at 5, 15, 30, 45, 60, and 90
min after drug administration and defined as the test latency (TL),
with a cutoff time of 10 s. The antinociceptive response was
expressed as the percentage of MPE = 100 × (TL − CL)/(10 − CL).
Intraperitoneal Acetic Acid-Induced
Writhing Test
Antinociception was evaluated in the different groups of mice
placed individually in a large glass cylinder for observation by
counting stretching or writhing responses during a 10-min period
after an i.p. injection of AcOH acid (0.1 ml/10 g of a 0.6%, w/v
solution in water). LOR17 or U50,488 (0–10 mg/kg) was i.p,
administered 5 minutes before AcOH, and the control group was
treated with an equal amount of vehicle (propylene glycol and
saline, 1:1 ratio) before administering the AcOH solution.
Oxaliplatin-Induced Cold Hypersensitivity
Test and Pharmacological Treatments
Oxaliplatin neuropathy was induced in mice administered 2.4
mg/kg oxaliplatin intraperitoneally (i.p.) for 5 consecutive days
each week for 2 weeks (Cavaletti et al., 2001; Brindisi et al., 2016).
Oxaliplatin was dissolved in 5% glucose solution. Control
animals received an equivalent volume of 5% glucose i.p.
(vehicle). LOR17 was dissolved in 1:1 saline/propylene glycol
solution, and U50,448 was dissolved in saline solution. For
acute experiments, both compounds were administered
subcutaneously (s.c.) on day 14 of the oxaliplatin treatment.
Alternatively, LOR17 was administered s.c. daily starting on the
first day of oxaliplatin injection. The cold plate test was
performed on day 14 to assess the acute effects (from 15–75
min after the injection of LOR17 or U50,448) and on days 7 and
14 to evaluate the effects of repeated treatment (24 h after the last
LOR17 administration). Eventual adverse effects induced by
LOR17 were evaluated 30 min after a single administration of
the compound (10 mg/kg, s.c.) in behavioral tests, namely, the
hole-board, rotarod, and forced swimming tests.
Cold Plate Test
The animals were placed in a stainless box (12 cm × 20 cm ×
10 cm) with a cold plate as the floor. The temperature of the cold
plate was kept constant at 4 ± 1°C. Pain-related behaviors (i.e.,
lifting and licking of the hind paw) were observed, and the timeFrontiers in Pharmacology | www.frontiersin.org 6(s) until the first sign was recorded. The cutoff time for the
latency to paw lifting or licking was set at 60 s (Carta et al., 2015).
Rotarod Test
The integrity of the animals’motor coordination was assessed, in
a different group of mice, using a rotarod apparatus (Ugo Basile,
Varese, Italy) at a rotating speed of 16 rpm. The treatment was
performed before the test. The numbers of falls from the rod were
counted for 30 s, before (0 min) and 15, 30, and 45 min after drug
administration, and the test was performed according to the
method described by Vaught et al. (1985).
Hole-Board Test
The hole-board test consisted of a 40 cm2 plane with 16 flush-
mounted cylindrical holes (3 cm diameter) distributed four by four
in an equidistant, grid-like manner. Mice were placed on the center
of the board one by one and allowed tomove about freely for a period
of 5 min. Two electric eyes, crossing the plane from midpoint to
midpoint of the opposite sides, thus dividing the plane into four
equal quadrants, automatically signaled themovement of the animal
(counts in 5min) on the surface of the plane (spontaneousmotility).
Miniature photoelectric cells in each of the 16 holes recorded (counts
in 5 min) the exploration of the holes (exploratory activity) by the
mice (Guerrini et al., 2006).
Forced Swimming Test
The forced swimming test was carried out as described by Porsolt
et al. (1977). Briefly, mice were placed individually into glass
cylinders (height: 25 cm, diameter: 10 cm) containing 12 cm of
water maintained at 22–23°C and left there for 6 min. A mouse
was judged to be immobile when it floated in the water, in an
upright position, and made only small movements to keep its
head above water. The duration of mobility was recorded during
the last 4 min of the 6-min test. An increase in the duration of
mobility is indicative of an antidepressant-like effect.
Blind Experiments
Researchers involved in the experiments, data collectors, outcome
adjudicators, and data analysts that did participate to the study
were blinded to reduce the risk of bias. Personnel who did not
perform the experiments prepared the administered compounds.
Materials
LOR17 was dissolved in a vehicle containing propylene glycol
and saline in a 1:1 ratio.
U50,488 was obtained by Tocris and dissolved in ultrapure
water for in vitro assays and in saline for in vivo experiments.
Polyacrylamide gel, ammonium persulfate, sodium dodecyl
sulfate, Tween 20, BSA, Triton-X-100, RNAlater, TRI Reagent,
and Phosphatase Inhibitor Cocktail 3 were obtained from Sigma-
Aldrich. Cell culture media, PBS, FBS, were from Thermo Fisher
Scientific. Secondary antibodies for western blot analysis were
from Santa Cruz Biotechnology (Santa Cruz, CA, USA), whereas
antibodies directed toward MAPK were from Cell Signaling.
Hybond-ECL nitrocellulose membrane was obtained from GE
Healthcare (Chicago, USA). All the plastic disposables were from
Sarstedt (Nümbrecht, Germany). All the other reagents were ofMarch 2020 | Volume 11 | Article 188
Bedini et al. LOR17: A Novel KOPr Analgesicanalytical grade or the highest purity available and purchased
from Sigma-Aldrich.
Data and Statistical Analysis
All in vitro data represent the mean ± SD of at least five
independent experiments, whereas for the in vivo warm-water
tail-withdrawal and writhing tests, at least eight animals per
group were analyzed. With regard to in vitro assays and in vivo
acetic acid-induced writhing, statistical analysis was performed
via GraphPad Prism 5.0 using one-way ANOVA and post hoc
Newman-Keuls tests. With regard to warm-water tail-withdrawal
test, statistical analysis was performed via GraphPad Prism 5.0
using two-way ANOVA. The data and statistical analysis comply
with the recommendations on experimental design and analysis
in pharmacology (Curtis et al., 2015). Regarding the oxaliplatin-
induced neuropathy test, rotarod test, hole-board test, and forced
swimming test, behavioral measurements were performed on 12
mice for each treatment carried out in 2 different experimental
sets. A Bonferroni’s significant difference procedure was used as a
post hoc comparison after ANOVA. IC50 and ED50 values were
calculated from the respective concentration- or dose-dependent
response curves via GraphPad Prism 5.0, by means of log
(agonist)vs.response (three parametric) equationRESULTS
Peptide Synthesis, General Procedure
The linear peptide precursor of LOR17 was synthesized on solid
phase in the presence of TBTU/HOBt/DIPEA under conditions
previously optimized (De Marco et al., 2017). Steps of FmocFrontiers in Pharmacology | www.frontiersin.org 7deprotection and coupling were repeated until the final linear
tetrapeptide was obtained. Phe-Gly-b-Ala-D-Trp was recovered
after cleavage with TFA and scavengers, and it was verified by
analytical RP-HPLC (see General Procedures). The cyclization
was performed under pseudo high dilution conditions using a
temporized syringe in the presence of HATU/DIPEA/DMF,
yielding c[Phe-Gly-b-Ala-D-Trp] (Figure 1B). The resulting
crude residue was purified by semi-preparative RP HPLC (see
General Procedures), and the cyclic peptide was characterized by
reversed-phase HPLC, 1H NMR and 13C NMR. Purities were
determined to be >95% by analytical RP-HPLC (see General
Procedures) and elementary analysis.
Binding Affinity of LOR17 to Different
Opioid Receptors
LOR17 affinity to mu, delta and kappa receptors was evaluated by
adopting a competition binding assay carried out in HEK-293/
hMOPr, HEK-293/hDOPr, or HEK-293/hKOPr cells using [3H]
DAMGO, [3H]-diprenorphine, or [3H]U69,593 as specific
radioligands, respectively, as described in the Methods. The
reference compounds DAMGO, DPDPE, and U50,488 showed
Ki values in the nM range and high selectivity to the respective
receptors (Table 1). LOR17 was a KOPr-selective ligand with a
nanomolar affinity for the kappa receptor (Table 1).
KOPr Expression and Inhibition of
Forskolin-Induced cAMP Accumulation in
HEK-293/hKOPr Cells, U87-MG Cells, and
Primary Human Astrocytes
Prior to assessing LOR17 activity at the kappa receptor, KOPr
density on the membranes of HEK-293/hKOPr cells, U87-MGFIGURE 1 | Structure of the natural peptide CJ-15,208 and the synthetic peptide Cyclo EM-1 (A) and synthesis of the peptide hybrid of the two sequences, LOR17
(B); i. 20% Pip/DMF, ii. HOBt/TBTU/DIPEA, iii. TFA/TIPS/PhOH/water, iv. HATU/DIPEA/DMF.March 2020 | Volume 11 | Article 188
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measure of KOPr protein expression levels by means of
saturation binding assays: kappa receptor density (BMax) was
1400 ± 220 fmol/mg in HEK-293/hKOPr cells, 412 ± 48 fmol/mg
in U87-MG cells, and 326.3 ± 127.9 fmol/mg in normal human
astrocytes (Table 2); KOPr expression, therefore, is significantly
lower in the employed astrocyte cells as compared to HEK-293/
KOPr cells (p < 0.001 vs HEK-293/hKOPR cells; Newman-Keuls
test after ANOVA) (Table 2). The apparent affinity of [3H]-
U69,593 to KOPr was similar in the three cell models, showing
Kd values of 1.3 ± 0.3 nM in HEK-293/hKOPr cells, 2.2 ± 0.6 nM
in U87-MG cells, and 2.0 ± 0.4 nM in normal human astrocytes
(Table 2).
LOR17 activity as a KOPr agonist was investigated by
measuring its ability to counteract forskolin-induced cAMP
accumulation in HEK-293/KOPr cells, U87-MG human
astrocytoma cells and normal human astrocytes. U50,488 was
assayed under the same experimental conditions as a KOPr-
selective reference agonist. As reported in Table 3, both U50,488
and LOR17 effectively inhibited forskolin-induced cAMP
accumulation in all three cell models employed, displaying
IC50 values in the nanomolar range and Emax values suggestive
of full agonism (Table 3). Furthermore, LOR17 and U50,488
potency and efficacy in inhibiting forskolin-induced cAMP
accumulation were not affected by the different KOPr
expression levels observed in the three cell models employed.Frontiers in Pharmacology | www.frontiersin.org 8LOR17 Biased KOPr Signaling Toward G
Protein Activation Over b-Arrestin 2
Recruitment
To investigate LOR17 and U50,488 ability to recruit b-arrestin 2
at KOPr, ligands were tested within the PathHunter b-arrestin 2
recruitment assay with U2OS cells co-expressing hKOPr and the
enzyme acceptor tagged b-arrestin 2 fusion protein. U50,488 was
tested in parallel under the same conditions as a reference full
KOPr agonist. We found that LOR17 induced a very week b-
arrestin 2 recruitment at KOPr and only at concentrations higher
than 1 mM (Figure 2B); on the other hand, both LOR17 and U50
determined a significant and similar inhibition of forskolin-
induced cAMP accumulation in HEK-293/hKOPr cells (Figure
2A). Concentration-response curves obtained by using the two
signaling assays above indicated were analyzed by using the
operational model (van der Westhuizen et al., 2014; Stahl et al.,
2015) in order to calculate the bias factor. Compared to U50,488,
that was normalized to a value of 1, bias factor for LOR17
resulted equal to 853. The transduction ratio (log(t/KA)) values
for compounds and assays are listed in Table 4.
Furthermore, LOR17 and U50,488 ability to recruit b-arrestin
2 at KOPr was assessed also by means of a BRET assay carried
out in HEK-293 cells as described in the Methods.
1 and 10 mM U50,488, but not 1 and 10 mM LOR17,
significantly increased the BRET ratio signal as compared to
vehicle treated cells, peaking the effect at 25 min of exposure
(Figure 2C). Consistently, b-arrestin 2 demonstrated saturable
agonist-induced binding to KOPr, measured as the difference
between the BRET ratio in the presence and absence of agonist
(net BRET) (Figure 2D), only when cells were exposed to
U50,488 and not to LOR17; these results are reflected by the
NetBRETmax values calculated from the Net Bret saturation
curves (Figure 2E).
Effects of U50,488 and LOR17 on ERK 1/2
and p38MAPK Phosphorylation
U50,488- and LOR17-mediated ERK1/2 and p38MAPK
phosphorylation was investigated in HEK-293/hKOPr cells,
U87-MG cells and human astrocytes by western blot analysis.
U50,488 (1 µM) significantly increased ERK1/2 phosphorylation
levels in all three cell models mentioned above, with peaks of
ERK1/2 activation at 5, 60, and 120 min in HEK-293/hKOR cells
(Figures 3A, B) (p < 0.05 vs Vehicle; Newman-Keuls test after
ANOVA), at 15 and 60 min in U87-MG cells (Figures 3D, E)
(p < 0.05 vs Vehicle; Newman-Keuls test after ANOVA) and at
15, 30, and 60 min in human astrocytes (Figures 3G, H).
LOR17 (1 µM) produced a significant increase in ERK1/2
phosphorylation only after 15 min of exposure; this effect was
similar in all three cell models employed in this study (FiguresTABLE 2 | Kappa opioid receptor (KOPr) density on cell membrane of different
cell models.
Cell model Bmax (fmol/mg) Kd (nM)
HEK-293/hKOPr 1400 ± 220 1.3 ± 0.3
U87-MG 412 ± 48*** 2.2 ± 0.6
NHA 326.3 ± 127.85*** 2.0 ± 0.4Mean of 6 determinations ± SD; ***p < 0.001 vs HEK-293/hKOPr (Newman-Keuls test
after ANOVA).TABLE 3 | Inhibitory effects of LOR17 and U50,488 on forskolin-induced cAMP accumulation in different cell models.
COMPOUND IC50 HEK-293/KOR (nM) EmaxHEK-293/KOR (%) IC50 U87-MG (nM) EmaxU87-MG (%) IC50 NHA (nM) EmaxNHA(%)
U50,488 1.6 ± 0.5 90 ± 2 1.2 ± 0.2 88 ± 3 2.2 ± 0.4 87 ± 3
LOR17 2.8 ± 0.6 85 ± 5 3.1 ± 0.8 87 ± 4 3.0 ± 0.2 88 ± 6March 2020 | Volume 11Mean ± SD of 6 independent experiments performed in triplicate.TABLE 1 | In vitro affinity of LOR17 and reference compounds to opioid
receptors.












U50,488 not peptide 2.90 ± 0.04
LOR17 c[Phe-Gly-(b-Ala)-D-Trp] >105 >105 1.19 ± 0.28Mean of 6 determinations ± SD.| Article 188
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after ANOVA).
Moreover, LOR17 (1mM)-mediated increase in ERK1/2
phosphorylation in HEK-293/hKOPr and U87-MG cells was
fully reverted by pre-administering the KOPr antagonist norBNI
(10 mM; 30 min prior to LOR17) (Figures 5A, B).
Regarding p38MAPK phosphorylation, it was significantly
enhanced in HEK-293/hKOPr cells, U87-MG cells and humanFrontiers in Pharmacology | www.frontiersin.org 9astrocytes after 30 min of exposure to 1 µM U50,488 (p < 0.05 vs
Vehicle; Newman-Keuls test after ANOVA) but not to 1 µM
LOR17. Furthermore, the latter does not influence p38MAPK
phosphorylation either at any of the time points chosen
(Figure 4) or at concentrations up to 100 mM (Figures 5C, D).
Moreover, LOR17 counteracted U50,488-induced p38MAPK
phosphorylation in a concentration-dependent fashion
(Figures 5E, F).FIGURE 2 | In vitro functional activity of LOR17 and U50,488. (A). Inhibition of forskolin-induced cAMP accumulation assessed via cAMP ELISA in HEK-293/hKOPr
cells. The data were normalized to the maximum stimulation caused by U50,488 (100%) (n = 5 independent experiments). (B). Concentration–response curves of
LOR17 and U50,488 for b-arrestin 2 recruitment to hKOPr expressed in U2OS–b-arrestin 2 cells using the PathHunter b-arrestin2 assay. Responses were
normalized to the maximum effect of U50,488 (100%) (n = 3 independent experiments). All data are presented as the mean ± SD. (C–E). BRET-based assays to
assess the interaction of increasing amounts of arrestin 3-YFP with luciferase-tagged human KOPr. (C). BRET ratio in the presence of U50,488, LOR17 or vehicle in
HEK-293 cells co-expressing varying amounts of arrestin 3-YFP with RLuc-tagged KOPr; means ± S.D. of six repeats in a representative experiment (of five
performed) are shown. (D). Agonist-induced increase in BRET as a function of arrestin 3-YFP expression normalized by RLuc luminescence (F/L); Means ± S.D. of
six repeats in a representative experiment (of five performed) are shown. (E). Net BRET Max values calculated from U50,488 or LOR17 response curves plotted in
panel D. *p < 0.05 vs LOR17 (t test).March 2020 | Volume 11 | Article 188
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U87-MG and Human Astrocyte Cell
Proliferation in a KOPr-Dependent,
b-Arrestin 2- and p38MAPK-Mediated
Fashion
It has been clearly demonstrated in animal models of
neuropathic pain (i.e., partial sciatic nerve ligation, partial
infraorbital nerve ligation, streptozotocin-induced pain) that
KOPr-dependent p38MAPK activation by endogenous
dynorphin may promote astrocyte activation and proliferation,
thus contributing to allodynia and hyperalgesia. Moving from
these considerations, the influence of U50,488 and LOR17 on
astrocyte cell proliferation was investigated via a [3H]-thymidine
incorporation assay in U87-MG cells and human astrocytes.
Concentration- and time-dependent responses were evaluated:
U50,488 (0–100 µM) induced a significant and concentration-
dependent increase in the U87-MG cell proliferation rate at both
24 h and 48 h (p < 0.05 vs Vehicle; Newman-Keuls test after
ANOVA), whereas LOR17 (0–100 µM) did not (Figures 6C, D).
The U50,488 (1 µM)-mediated increase of U87-MG cell
proliferation following 24 h and 48 h of exposure was
prevented by the KOPr-selective antagonist norBNI (10 µM; 15
min prior to U50,488) as well as by siRNA selective for b-arrestin
2 (50 nM; 48 h) or by the p38MAPK inhibitor SB203580 (2 µM;
30 min prior to U50,488) (Figure 6A) (p < 0.05 vs U50,488;
Newman-Keuls test after ANOVA). In contrast, LOR17 (1 µM)
did not alter the U87-MG cell proliferation rate at either 24 h or
48 h of exposure (Figure 6A), not even when administered at
concentration up to 100 mM (Figures 6C, D). Moreover, when
10 mM LOR17 was co-administered together with 1 mMU50,488,
the former prevented the increase in U87-MG cell proliferation
induced by the latter (Figure 6A).
Similarly, 1 µM U50,488, but not 1 µM LOR17, significantly
enhanced normal human astrocyte cell proliferation (p < 0.05 vs
Vehicle; Newman-Keuls test after ANOVA), and this effect was
abolished by the p38MAPK inhibitor SB203580 (2 µM; 30 min
prior to U50,488) (Figure 6B) (p < 0.05 vs U50,488; Newman-
Keuls test after ANOVA). The b-arrestin 2 selective siRNA
significantly knocked-down b-arrestin 2 expression in U87-
MG cells, as confirmed by western blot (Figure 6E) (p < 0.05
vs Vehicle and Ctrl siRNA; Newman-Keuls test after ANOVA).Frontiers in Pharmacology | www.frontiersin.org 10U50,488 and LOR17 Promote
Antinociceptive Effects in Different Models
of Nociceptive Pain
U50,488- and LOR17-mediated antinociception was investigated
in adult male mice via the warm-water tail-withdrawal test and
by the writhing test, as described in the Methods.
U50,488 and LOR17 display similar dose-response curves at
30 min after i.p. injection, yielding to comparable ED50 values in the
warm-water tail-withdrawal test (Figures 7A, B). In the warm-water
tail-withdrawal test, ED50 was equal to 10.07 ± 0.36 mg/kg (95% C.I.
9.82–10.32 mg/kg) for LOR17 and to 9.93 ± 0.37 mg/kg (95% C.I.
9.66–10.19 mg/kg) for U50,488; in the writhing test, ED50 was equal
to 5.74 ± 0.46 mg/kg (95% C.I. 5.41–6.07 mg/kg) for LOR17 and to
8.24 ± 0.59 mg/kg (95% C.I. 7.82–8.66 mg/kg) for U50,488.
U50,488 (0–20 mg/kg, 0–60 min; i.p.) produced a significant,
dose- and time-dependent antinociception in the tail-withdrawal
test (Figure 7C). LOR17 (0–20 mg/kg, 0–90 min; i.p.) promoted
an antinociceptive response in a dose- and time-dependent
fashion, displaying its effects starting at 30 min after injection
and lasting up to 60 min after administration (at least with regard
to the highest dose employed) (Figure 7D). LOR17-mediated
antinociception was prevented by i.p. administration of the
KOPr-selective antagonist norBNI (10 mg/kg) (Figure 7D).
Abdominal contractions induced upon i.p. injection of 0.6%
acetic acid were adopted as a measure of visceral pain; within
this experimental setting, pre-emptive i.p. administration of
both U50,488 and LOR17 (0–10 mg/kg) significantly reduced
the number of writhes (Figures 7E, F) (p < 0.05 vs Vehicle;
Newman-Keuls test after ANOVA).
LOR17, but Not U50,488, Significantly
Reduces Thermal Hypersensitivity in a
Mouse Model of Oxaliplatin-Induced
Neuropathic Pain After Both Single and
Repeated s.c. Administration
A cumulative dose of oxaliplatin induces the development of a
painful neuropathy as evaluated by the measurement of the
response to a thermal stimulus. On day 14 of oxaliplatin
treatment, mice injected with oxaliplatin showed a decrease in
the pain threshold evaluated by the cold plate test (Figure 8). A
single administration of s.c. LOR17 increased the licking latency in
a dose-related manner, taking effect from 1 mg/kg (Figure 8A). At
doses of 10 and 20 mg/kg, LOR17 fully reversed the oxaliplatin-
dependent hypersensitivity, peaking between 30 and 45 min after
s.c. administration. Conversely, U50,488 could significantly reduce,
at least in part, oxaliplatin-induced thermal hypersensitivity when
administered at 20 mg/kg (Figure 8B). However, the maximal
effect elicited by U50,488, when administered at 10 or 20 mg/kg,
was significantly lower as compared to the maximal effect induced
by similar doses of LOR17 (Table 5). Furthermore, this newly
synthesized KOPr agonist had an ED50 value of 6.63 ± 0.23 mg/kg
(95% C.I. 6,49–6,77 mg/kg); on the other hand, it was not possible
to calculate the corresponding ED50 value for U50,488
administered up to 20 mg/kg.
Aimed at evaluating the pain-relieving profile of LOR17
following repeated treatments, this compound (10 mg/kg) wasTABLE 4 | Analysis of bias comparing G protein signaling and b-arrestin2
recruitment induced by LOR17 in comparison to U50,488 activity.












U50,488 8,595 6,102 0 0 0 1
LOR17 8,856 3,432 0,261 -2,67 2,931 853aDerived from the cAMP ELISA assay carried out in HEK-293 cells expressing the human
KOP receptor (n = 5 independent experiments). bDerived from the PathHunter b-arrestin2
recruitment assay with U2OS cells co-expressing the human KOP receptor and the
enzyme acceptor tagged b-arrestin 2 fusion protein (n = 3 independent experiments).
Transduction coefficients ((log(t/KA), mean ± SEM), and bias factors (DDlog(t/KA)G
protein - b-arrestin 2) were calculated using the operational model.March 2020 | Volume 11 | Article 188
Bedini et al. LOR17: A Novel KOPr AnalgesicFIGURE 3 | U50,488- and LOR17-mediated phospho-ERK1/2 (P-ERK1/2) increase in HEK-293/hKOPr cells, U87-MG astrocytoma cells and normal human
astrocytes. (A). Representative blots of HEK-293/hKOPr cells exposed to 1 µM U50,488, 1 µM LOR17 or vehicle. (B, C). Quantification of P-ERK levels in HEK-293/
hKOPr cells exposed to 1 µM U50,488, 1 µM LOR17 or vehicle; data are presented as the mean ± SD of 6 independent experiments. *p < 0.05 vs vehicle
(Newman-Keuls test after ANOVA). (D). Representative blots of U87-MG human astrocytoma cells exposed to 1 µM U50,488, 1 µM LOR17 or vehicle. (E, F).
Quantification of P-ERK levels in U87-MG human astrocytoma cells exposed to 1 µM U50,488, 1 µM LOR17 or vehicle; data are presented as the mean ± SD of 6
independent experiments. *p < 0.05 vs vehicle (Newman-Keuls test after ANOVA). (G). Representative blots of normal human astrocytes exposed to 1 µM U50,488,
1 µM LOR17 or vehicle. (H, I). Quantification of P-ERK levels in normal human astrocytes exposed to 1 µM U50,488, 1 µM LOR17 or vehicle; data are presented as
the mean ± SD of 6 independent experiments. *p < 0.05 vs vehicle; **p < 0.01 vs vehicle (Newman-Keuls test after ANOVA).Frontiers in Pharmacology | www.frontiersin.org March 2020 | Volume 11 | Article 18811
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administration. This dose was selected as it was the lowest
dose giving rise to the maximal effect, as assessed after acute
LOR17 administration. The cold plate test assessed on days 7 and
14, 24 h after the administration of LOR17, revealed that LOR17
maintains its efficacy (Figure 8C); thus, dispelling any
development of tolerance.
LOR17 Does Not Alter Motor Coordination,
Locomotor, and Exploratory Activities and
Does Not Induce Pro-Depressant-Like
Behavior
The relieving effect of LOR17 in oxaliplatin-induced thermal
hypersensitivity is free from behavioral side effects. Motor
coordination (Table 6, rotarod test) as well as locomotor and
exploratory activities (Table 6; hole-board test) were unalteredFrontiers in Pharmacology | www.frontiersin.org 12after LOR17 administration (10 mg/kg, s.c.). Finally, LOR17 (10
mg/kg, s.c.) did not induce pro-depressant-like behavior as
evaluated by the forced swimming test (Table 6). Conversely,
10 mg/kg U50,488 significantly altered rotarod performance and
reduced mobility time in the Prosolt test (Table 6). The dose of 10
mg/kg was selected as it was the lowest dose giving rise to the
LOR17-mediated maximal effect in the oxaliplatin-induced
neuropathic mice, as assessed after acute LOR17 administration;
in fact, U50,488 administered at the same dose was not effective in
relieving oxaliplatin-induced thermal hypersensitivity.DISCUSSION AND CONCLUSION
Several studies have proposed that KOPr agonists induce
antinociception by activating G protein-mediated cell signaling,FIGURE 4 | U50,488 and LOR17-mediated phospho-p38MAPK (P-p38) increase in HEK-293/hKOPr cells, U87-MG astrocytoma cells and normal human
astrocytes. (A). Representative blots and quantification of P-p38 levels in HEK-293/hKOPr cells exposed to U50,488 (1 µM; 30 min), LOR17 (1 µM; 30 min) or
vehicle; data are presented as the mean ± SD of 6 independent experiments. *p < 0.05 vs vehicle (Newman-Keuls test after ANOVA). (B, C). Representative blots
and quantification of P-p38 levels in U87-MG human astrocytoma cells exposed to 1 µM U50,488, 1 µM LOR17 or vehicle; data are presented as the mean ± SD of
6 independent experiments. *p < 0.05 vs vehicle (Newman-Keuls test after ANOVA). (D, E). Representative blots and quantification of P-p38 levels in normal human
astrocytes exposed to 1 µM U50,488, 1 µM LOR17 or vehicle; data are presented as the mean ± SD of 6 independent experiments. *p < 0.05 vs vehicle (Newman-
Keuls test after ANOVA).March 2020 | Volume 11 | Article 188
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FIGURE 5 | LOR17 increased P-ERK levels in a KOPr-dependent way and did not increase P-p38 levels in HEK-293/hKOPr and U87-MG cells, even when
administered at concentrations up to 100 mM. (A). Representative blots and quantification of P-ERK levels in HEK-293/hKOPr cells exposed to norBNI (10 µM; 30
min prior to LOR17) and LOR17 (1 µM; 15 min), LOR17 (1 mM; 15 min) alone or vehicle; data are presented as the mean ± SD of 6 independent experiments.*p <
0.05 vs vehicle (Newman-Keuls test after ANOVA). (B). Representative blots and quantification of P-ERK levels in U87-MG cells exposed to norBNI (10 µM; 30 min
prior to LOR17) and LOR17 (1 µM; 15 min), LOR17 (1 mM; 15 min) alone or vehicle; data are presented as the mean ± SD of 6 independent experiments. *p < 0.05
vs vehicle (Newman-Keuls test after ANOVA). (C). Representative blots and quantification of P-p38 levels in HEK-293/hKOPr cells exposed to LOR17 (1-100 µM; 30
min) or vehicle; data are presented as the mean ± SD of 6 independent experiments. (D). Representative blots and quantification of P-p38 levels in U87-MG cells
exposed to LOR17 (1-100 µM; 30 min) or vehicle; data are presented as the mean ± SD of 6 independent experiments. (E). Representative blots and quantification
of P-p38 levels in HEK-293/hKOPr cells exposed to vehicle, U50,488 (1 µM; 30 min) alone or co-administered with LOR17 (0.01-10 µM; 30 min); data are presented
as the mean ± SD of 6 independent experiments. (F). Representative blots and quantification of P-p38 levels in U87-MG cells exposed to vehicle, U50,488 (1 µM; 30
min) alone or co-administered with LOR17 (0.01-10 µM; 30 min); data are presented as the mean ± SD of 6 independent experiments. *p < 0.05 vs vehicle; #p <
0.05 vs U50,488 (Newman-Keuls test after ANOVA).
Bedini et al. LOR17: A Novel KOPr Analgesicincluding adenylyl cyclase inhibition and early ERK1/2
phosphorylation. Conversely, KOPr-mediated p38MAPK
activation contributes to dysphoria and aversion (Bruchas et al.,
2007; Ehrich et al., 2015) as well as to sedation and motor
incoordination (Bruchas and Roth, 2016). Furthermore, activation
of this latter signaling pathway promotes partial sciatic nerve ligation
(pSNL)-induced astrocyte proliferation and subsequent hyperalgesia
and thermal allodynia (Clayton et al., 2009), and contributes to the
modulation of potassium channel heterologous desensitization,
possibly leading to antinociceptive tolerance (Xu et al., 2007).
The foremost finding of this study is that LOR17 inhibits
adenylyl cyclase to a similar extent as compared to U50,488, but
does not significantly recruit b-arrestin 2 at KOPr, displaying a
bias factor of 853 toward G protein activation over b-arrestin 2
recruitment. Consistently, LOR17 activates early ERK1/2
phosphorylation in different cell models, whereas contrary to
U50,488, it does not activate p38MAPK and does not promote b-
arrestin 2-dependent, p38MAPK-mediated astrocyte cell
proliferation. Similar to U50,488, LOR17 is effective in animal
models of acute nociception. LOR17, more effectively than
U50,488, reduces thermal hypersensitivity in a mouse model of
oxaliplatin-induced neuropathic pain after both single or
repeated s.c. administrations, without altering, in the range of
administered doses, motor coordination, locomotor, and
exploratory activities and without inducing pro-depressant-
like effects.
Thus, LOR17 emerges as a novel, potent and G protein biased
KOPr selective agonist with a more favorable in vitro and in vivo
pharmacological profile compared to the classic kappa agonist
U50,488. Functionally selective ligands, as LOR17, are indeed
valuable research tools to deeply explore and characterize which
pharmacological responses are specifically connected to distinct
signaling events; thus, allowing to fully understand if and to what
extent biased agonism at kappa receptor may be translated into
innovative analgesics with reduced adverse effects and low
abuse liability.
Notably, functional selectivity at opioid receptors has been
intensely investigated in the last decade aiming at identifying
more effective and safer analgesics, as many of the unwanted
effects determined by MOPr or KOPr agonists are reduced or
absent in b-arrestin-2 knock-out mice (Bohn et al., 2000; Raehal
et al., 2005; Li et al., 2009; Bruchas and Roth, 2016). Therefore,
increasing efforts have been devoted to developing functionally
selective opioid agonists displaying a limited activation of
arrestin-dependent signaling pathways.Frontiers in Pharmacology | www.frontiersin.org 14Oliceridine is one of the firstMOPrG protein pathway-selective
modulators that had undergone phase-IIb clinical trials for the
management of moderate to severe acute pain following
abdominoplasty (Singla et al., 2017); after that, Oliceridine
completed also Phase III clinical trials, but in October 2018 the
US FDA decided not to approve it, due to doubts whether the
benefits associated with the drug outweighed the risks (Mores et al.,
2019).Thisdecision significantlydampened the enthusiasmaround
biased agonists at opioid receptors (especially atMOPr) as potential
improved analgesics. However, FDA decision was taken with 8
votes for rejection and 7 votes for approval; thus highlighting once
more that the potential utility of biased agonists at opioid receptors
is still highly debated and cannot be completely ruled out at the
moment; thus, suggesting that further studies are necessary to fully
understand if and how it will be possible to develop novel opioid
analgesics more effective and safer than morphine by exploiting
functional selectivityat opioid receptors.Moreover, althoughbiased
agonism atMOPr has been so far disappointing in terms of getting
novel therapeutics into themarket, functional selectivity at KOPr is
still considered interesting and potentially promising: it is believed,
in fact, that the whole kappa opioid field will greatly benefit from
future studies aimed at analyzing novel compounds on one hand,
and at correlating the degree of signaling bias to particular
pharmacological responses on the other (Mores et al., 2019).
Within this perspective, we believe that our findings on LOR17
may represent a significant advance.
Regarding functionally selective KOPr agonists, to our
knowledge, no any compound has reached clinical trials so far;
nevertheless, the finding that KOPr-induced antinociception is G
protein dependent, whereas KOPr-mediated dysphoria
correlates with p38MAPK-mediated events (Bruchas and
Chavkin, 2010), had significantly boosted studies aimed at
developing new KOPr agonists with a limited activation of
p38MAPK-dependent signaling; thus leading to the
identification of different innovative ligands targeting KOPr.
Among these agents, MPCIE, a novel 1-pyrazole methyl ester
derivative, elicited KOPr-mediated antinociception without
producing sedation, constipation or motor impairment in
different models of inflammatory and neuropathic pain
(Trevisan et al., 2013); however, the molecular determinants of
the MPCIE advantageous profile were not further elucidated.
Zhou and colleagues, on the other hand, have described two
classes of biased KOPr agonists potently activating G protein
coupling but weakly recruiting b-arrestin-2. The most effective
compound of each of these classes (i.e., triazole 1.1 andMarch 2020 | Volume 11 | Article 188
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FIGURE 6 | U50,488- and LOR17-mediated effects on cell proliferation of U87-MG human astrocytoma cells and normal human astrocytes. (A). U50,488 (1 µM)
produced a KOPr-dependent, b-arrestin 2- and p38MAPK-mediated increase in the U87-MG cell proliferation rate, whereas LOR17 did not; LOR17 counteracted
U50,488-mediated induction of U87-MG cell proliferation. Data are presented as the mean ± SD of 8 independent experiments. *p< 0.05 vs vehicle, LOR17 (1 µM;
24 h) and LOR17 (1 µM; 48 h); **p< 0.01 vs vehicle, LOR17 (1 µM; 24 h) and LOR17 (1 µM; 48 h); #p< 0.05 vs U50,488 (1 µM; 24 h) and U50,488 (1 µM; 48 h);
##p< 0.01 vs U50,488 (1 µM; 24 h) and U50,488 (1 µM; 48 h) (Newman-Keuls test after ANOVA). (B). U50,488 (1 µM) resulted in a p38MAPK-mediated increase in
the normal human astrocyte cell proliferation rate, whereas LOR17 did not. Data are presented as the mean ± SD of 8 independent experiments. *p < 0.05 vs
vehicle, LOR17 (1 µM; 48 h) and SB203580 + U50,488 (Newman-Keuls test after ANOVA). (C, D). U50,488 (0.1-100 µM) produced a concentration-dependent
increase in the U87-MG cell proliferation rate at both 24 and 48 h of exposure, whereas LOR17 (0.1-100 µM) did not. Data are presented as the mean ± SD of 8
independent experiments. *p< 0.05 vs vehicle; **p < 0.01 vs vehicle (Newman-Keuls test after ANOVA). (E). Knock-down of beta-arrestin 2 expression in U87-MG
cells by means of selective siRNA. Data are presented as the mean ± SD of 6 independent experiments. §p < 0.001 vs Vehicle and Ctr siRNA (Newman-Keuls test
after ANOVA).
Bedini et al. LOR17: A Novel KOPr Analgesicisoquinolinone 2.1), though, was initially assayed only in the warm-
water tail-flick assay, displaying antinociceptive effects similar to
U50,488 (Zhou et al., 2013).More recently, triazole 1.1 was shown to
induce dose-dependent, KOPr-mediated antinociception and to
suppresses chloroquine phosphate–induced scratching responses
in C57BL/6 mice without affecting ambulatory behaviors in mice
(Brust et al., 2016). Furthermore, antinociception devoid of
dysphoria promoted by a KOPr-selective, G-protein-biased
agonist, was demonstrated also by other authors (Spetea et al.,
2017). On the other hand, White and co-workers have reported
that the G protein-biased KOPr agonist RB-64 induces
antinociceptive effects in the hot-plate test without impairing
rotarod performance or novelty-induced locomotion. Surprisingly,
RB-64 is aversive in the conditioned place preference paradigm,
albeit it does not involve b-arrestin-2 recruitment at the kappa
receptor (White et al., 2015); however, RB-64 did not increase
anhedonia in rodents as compared to vehicle in the ICSS
paradigm (White et al., 2015). Recently, three KOPr agonists
provided with different degrees of functional selectivity toward G
protein-dependent signaling were characterized with regard to their
neuroendocrine and behavioral effects (Dunn et al., 2018): KOPr-
dependent sedative effects elicited by these ligands were symmetrical
to their ability to recruit b-arrestin2 at KOPr. Thus, taken together,
these data support the hypothesis that downstream of KOPr
activation, sedation, coordination impairment and anhedonia may
be due to b-arrestin-2 recruitment and aversion possibly related, at
least in rodents, to arrestin-independent p38MAPK activation
(White et al., 2015).
Our results may represent a significant breakthrough in the
understanding of functional selectivity at KOPr and in the
development of innovative analgesics.
LOR17, in fact, displayed affinity and selectivity toKOPr similar
to the classic kappa agonist U50,488; moreover, both LOR17 and
U50,488 significantly inhibited adenylyl cyclase (a G protein-
mediated signaling event) in three different cell models expressing
hKOPr either exogenously or endogenously, and displayed
comparable IC50 and Emax values across the different cell models.
However, conversely to U50,488, LOR17 did not induce an
efficient b-arrestin 2 recruitment at KOPr. The above mentioned
differential signaling profile could also be explained in terms of low
efficacy, stimulus amplification and receptor reserve (Conibear and
Kelly, 2019). Comparing a G protein-dependent output that
encompasses high amplification (e.g.: inhibition of cAMP
accumulation) to arrestin recruitment at the receptor (which
displays little or no amplification) may lead, in fact, to define asFrontiers in Pharmacology | www.frontiersin.org 16“biased” ligands that arenotbiasedat all (Conibear andKelly, 2019).
However, LOR17 inhibited adenylyl cyclase in all the three cell
models employed, displaying potency and efficacy similar to
U50,488 regardless the significantly reduced KOPr expression
levels in U87-MG cells and in human astrocytes as compared to
HEK-293/KOPr; thus, supporting the conclusion that LOR17 may
be defined as biased toward G protein-mediated signaling.
It has been demonstrated that G protein signaling modulates
KOPr-induced antinociception; consistently, both LOR17 and
U50,488 produced significant antinociception in two different
mouse models of nociceptive pain. These results are in line with
the effects elicited by other functionally selective kappa agonists
(e.g., triazole 1.1, isoquinolinone 2.1, RB-64) that in comparable
paradigms induced antinociception similarly to classic kappa
agonists such as U50,488 or U69,593.
In HEK-293/hKOPr cells, in U87-MG cells and in human
astrocytes, LOR17 increased ERK1/2 phosphorylation in a KOR-
dependent way only after 15 min of exposure, whereas U50,488
triggers early (5–15 min) and late phase (60–120 min) ERK1/2
phosphorylation. This multi-phasic ERK1/2 phosphorylation by
classic kappa agonists has already been reported in type-1
immortalized rat cortical astrocytes, and it was hypothesized that
early ERK1/2 activation was G protein dependent and that late
ERK1/2 phosphorylation could be arrestin-mediated (McLennan et
al., 2008). Schattauer and colleagues have shown that acute hKOPr-
mediated ERK1/2 activation did not require arrestin recruitment,
whereas late phase hKOPr-mediated ERK1/2 phosphorylation was
arrestin-dependent (Schattauer et al., 2012). Furthermore, these
authors have demonstrated that b-arrestin-2 was necessary for
hKOPr-induced p38MAPK phosphorylation (Schattauer et al.,
2012), similarly to findings showing that p38MAPK activation
downstream of rat KOPr is GRK3- and arrestin-dependent
(Bruchas et al., 2006). In HEK-293/hKOPr cells, U87-MG cells
and in human astrocytes, LOR17 did not increase p38MAPK
phosphorylation even when administered at concentrations up to
100 mM, whereas U50,488 significantly activated it after 30 min of
exposure, consistentwith a previous report (Schattauer et al., 2012).
Moreover, in HEK-293/hKOPr cells and U87-MG cells, LOR17
counteracted U50,488-mediated increase in p38MAPK
phosphorylation in a concentration-dependent way. This result is
consistent with G-protein-signaling bias for LOR17, but it is also
consistent with low efficacy and partial agonism of LOR17 at KOR
(Conibear and Kelly, 2019).
Notably, nalfurafine (a moderately selective KOPr analgesic
with a low incidence of dysphoric effects used in Japan to treatMarch 2020 | Volume 11 | Article 188
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FIGURE 7 | Antinociceptive effects mediated by U50,488 and LOR17 in mice; vehicle (saline for U50,488 and 1:1 mixture of propylene glycol and saline for LOR17),
U50,488 or LOR17 were administered i.p. (A). Dose-response curve of the antinociceptive effect induced in the warm-water tail-withdrawal test by i.p. administered
U50,488. Data are presented as the mean ± SD of 10 mice. *p < 0.05 vs vehicle and U50,488 5 mg/kg; ***p < 0.001 vs vehicle and U50,488 5 mg/kg (Newman-
Keuls test after ANOVA). (B). Dose-response curve of the antinociceptive effect induced in the warm-water tail-withdrawal test by i.p. administered LOR17. Data are
presented as the mean ± SD of 10 mice. *p < 0.05 vs vehicle and LOR17 5 mg/kg; ***p < 0.001 vs vehicle and LOR17 5 mg/kg (Newman-Keuls test after ANOVA).
(C). U50,488 produced a time- and dose-dependent antinociception in the warm-water tail-withdrawal test. Data are presented as the mean ± SD of 10 mice. *p <
0.05 vs vehicle and U50,488 5 mg/kg; ***p < 0.001 vs vehicle and U50,488 5 mg/kg (Newman-Keuls test after ANOVA). (D). LOR17 determined a time- and dose-
dependent, KOPr-mediated antinociception in the warm-water tail-withdrawal test. Data are presented as the mean ± SD of 10 mice. *p < 0.05 vs vehicle and
LOR17 5 mg/kg; **p < 0.01 vs vehicle; ***p < 0.001 vs vehicle, LOR17 5 mg/kg, norBNI 10 mg/kg + LOR17 20 mg/kg and norBNI (10 mg/kg; 24 h) + LOR17 (20
mg/kg; 30 min**p < 0.01 vs vehicle) (Newman-Keuls test after ANOVA). (E). U50,488 dose-dependently reduced the number of abdominal writhes induced in mice
after i.p. injection of 0.6% acetic acid. Data are presented as the mean ± SD of 10 mice. çp < 0.05 vs vehicle; ççp < 0.01 vs vehicle;
§
p< 0.05 vs 1 mg/kg (Newman-
Keuls test after ANOVA). (F). LOR17 dose-dependently reduced the number of abdominal writhes induced in mice after an i.p. injection of 0.6% acetic acid. Data are
presented as the mean ± SD of 10 mice. çp < 0.05 vs vehicle; ççp < 0.01 vs vehicle (Newman-Keuls test after ANOVA).
Bedini et al. LOR17: A Novel KOPr AnalgesicFIGURE 8 | Effect of LOR17 on oxaliplatin-induced neuropathic pain. (A). Acute treatment: on day 14 of oxaliplatin administration (2.4 mg/kg, i.p., administered
daily), LOR17 (1 – 20 mg/kg) was administered s.c. The response to a thermal non-noxious stimulus was evaluated over time by the cold plate test measuring the
latency to pain-related behaviors (lifting or licking of the paw). (B). LOR17 effects were compared with those induced by the acute administration of U50,448 (10 and
20 mg/kg, s.c.). (C). Repeated treatment: LOR17 (10 mg/kg) was administered s.c. daily starting the first day of oxaliplatin treatment. Cold hypersensitivity (cold plate
test) was performed on days 7 and 14. Each value represents the mean ± S.E.M. of 12 mice performed in 2 different experimental set. **P < 0.01 versus vehicle +
vehicle treated animals; ^P < 0.05 versus oxaliplatin + vehicle; ^^P < 0.01 versus oxaliplatin + vehicle (Bonferroni test after ANOVA).Frontiers in Pharmacology | www.frontiersin.org March 2020 | Volume 11 | Article 18818
Bedini et al. LOR17: A Novel KOPr Analgesicuremic pruritus) resulted in biased ERK1/2 activation compared
to p38MAPK induction in hKOPr-expressing HEK-293 cells and
displayed antinociceptive effects in the tail immersion test
(Schattauer et al., 2017) as well as in other species and
preclinical pain models (Endoh et al., 2000); thus, further
sustaining interest in developing KOPr agonists that result in
limited p38MAPK phosphorylation (e.g., LOR17). However, it
should be noted that nalfurafine was recently demonstrated not
to be effective in relieving pain-depressed behaviors (Lazenka et
al., 2018); consistently, nalfurafine is not indicated as analgesic
drug not even in Japan (where it is marketed as an anti-itch
drug). These limited effects displayed by nalfurafine may be
related to a G protein signaling bias not high enough to produce
a desirable profile of antinociceptive efficacy and safety (Lazenka
et al., 2018); thus, pointing at the magnitude of bias factor as
another element to be considered when developing new KOPr
biased agonists. LOR17 displayed a bias factor of 853 as
compared to U50,488, thus emerging as a candidate compound
that is worthy of further characterization.
In the present study, we report that U50,488 increased U87-
MG astrocytoma and normal human astrocyte cell proliferation
in a KOP-dependent, b-arrestin 2- and p38MAPK-mediatedFrontiers in Pharmacology | www.frontiersin.org 19fashion, whereas LOR17 did not cause this effect. These
findings are relevant considering that U50,488 promotes type
II cultured mouse astrocyte cell proliferation (Xu et al., 2007).
In this regard, it is important to remind that the release of the
KOPr endogenous agonist dynorphin is significantly increased in
at least some animal models of neuropathic pain, including pSNL,
partial infraorbital nerve ligation, streptozotocin-induced pain
(Jolivalt et al., 2006; Xu et al., 2007; Aita et al., 2010); thus, it
potentially involves an initial antinociception due to dynorphin-
mediated KOPr activation in neurons followed by neuropathy-
induced allodynia and hyperalgesia that may be sustained by
dynorphin-evoked KOPr-dependent activation of p38MAPK in
astrocytes. Conversely, KOPr agonists inducing G protein
signaling without activating p38MAPK (as does LOR17) may
promote antinociception by binding to kappa receptors expressed
in neurons and may counteract KOPr-dependent p38MAPK
activation promoted by endogenous dynorphin by binding to
kappa receptor expressed in astrocytes; thus reducing, or possibly
preventing, endogenous dynorphin’s detrimental effects. Within
this frame, our findings showing that LOR17 counteracts in a
concentration-dependent fashion the increase in astrocyte cell
proliferation induced by U50,488 are relevant, as they support the
hypothesis that LOR17 is indeed able to counteract arrestin-
mediated outcomes triggered by classic KOPr agonists.
LOR17 significantly reduced thermal hypersensitivity after
both acute and repeated subcutaneous injections in a mouse
model of oxaliplatin-induced neuropathic pain; thus, suggesting
that LOR17 is effectively absorbed following peripheral
administration and does not cause tolerance after repeated
administrations. Conversely, U50,488 significantly reduced
reduces thermal hypersensitivity only when administered at 20
mg/kg. This functional selectivity displayed in vivo by LOR17,
compared to U50,488, may be related to the lack of p38MAPK
activation by the former agent. No information has been
reported on endogenous dynorphin release in the oxaliplatin-
induced neuropathy paradigm adopted. However, this
neuropathy model has been characterized with regard to
peripheral and central glial activation, showing initial
microglial activation followed by a more prolonged astrocyticTABLE 5 | Maximal effects elicited by LOR17 and U50,488 in counteracting
oxaliplatin induced thermal hypersensitivity, as compared to vehicle.
Treatment Licking latency (s)
oxaliplatin/vehicle 11.4 ± 1.2
oxaliplatin/U50,488 (10 mg/kg; 30 min) 12.6 ± 1.7
oxaliplatin/LOR17 (10 mg/kg; 30 min) 18.2 ± 1.4***
oxaliplatin/U50,488 (20 mg/kg; 30 min) 15.8 ± 1.6
oxaliplatin/LOR17 (20 mg/kg; 45 min) 19.6 ± 1.7***On day 14 of oxaliplatin administration (2.4 mg/kg, i.p., administered daily), LOR17 or
U50,488 (10 and 20 mg/kg) were administered s.c. The response to a thermal non-
noxious stimulus was evaluated over time by the cold plate test measuring the latency to
pain-related behaviors (lifting or licking of the paw). Maximal effects elicited in the dose-
response curve (see Figures 8A, B) are reported as compared to vehicle. Data are
presented as the mean ± SD of 10 mice. ***p < 0.001 vs oxaliplatin/vehicle, oxaliplatin
U50,488 (10 mg/kg; 30 min), oxaliplatin/U50,488 (20 mg/kg; 30 min); n = 12 (Newman-




Number of fallsa Holeb Boardb Mobility time (s)c
0 min 15 min 30 min 45 min 0 min 30 min 0 min 30 min
vehicle 3.0 ± 0.6 2.3 ± 0.3 1.8 ± 0.6 1.3 ± 0.3 42.4 ± 4.6 48.2 ± 4.1 81.6 ± 13.1 106.2 ± 8.0 80.5 ± 9.6
LOR17 10 2.8 ± 0.7 1.6 ± 0.4 1.2 ± 0.2 0.6 ± 0.2 37.2 ± 3.9 39.0 ± 4.6 89.2 ± 7.3 97.2 ± 16.9 91.6 ± 12.3
U50,488 10 2.9 ± 0.4 3.2 ± 0.5§ 2.6 ± 0.3§§ 2.1 ± 0.4§§ / / / / 21.0 ± 7.7 ***March 2020 | VolumaRotarod test: LOR17 was dissolved in 1:1 saline solution/propylene glycol mixture and subcutaneously administered. The integrity of motor coordination of the mouse was assessed on
the basis of the number of falls from the rod in 30 s The performance time was measured before (0 min) and 15, 30, and 45 min after the beginning of the test. § p < 0.05 vs vehicle and
LOR17; §§p < 0.01 vs vehicle and LOR17; n = 12 (Newman-Keuls test after ANOVA).
bHole-board test: LOR17 was dissolved in 1:1 saline solution/propylene glycol mixture and subcutaneously administered 25 min before the beginning of the test. Two electric eyes,
crossing the plane from midpoint to midpoint of opposite sides, thus dividing the plane into four equal quadrants, automatically signalled the movement of the animal (counts in 5 min) on
the surface of the plane (locomotor activity). Miniature photoelectric cells, in each of the 16 holes, recorded (counts in 5 min) the exploration of the holes (exploratory activity) by the mice.
cForced swimming test: LOR17 was dissolved in 1:1 saline solution/propylene glycol mixture and subcutaneously administered 25 min before the beginning of the test. Briefly, mice were
placed individually into glass cylinders, containing water, and left there for 6 min. The duration of mobility time during the last 4 min was recorded. *** p < 0.001 vs vehicle and LOR17; n = 12
(Newman-Keuls test after ANOVA).e 11 | Article 188
Bedini et al. LOR17: A Novel KOPr Analgesicreactive state in the spinal cord and in different brain regions
related to nociception (Di Cesare Mannelli et al., 2013). Thus,
these data further support the suggestion that the noteworthy
effectiveness of LOR17 in counteracting oxaliplatin-induced
neuropathic behaviors may rely on the lack of p38MAPK-
dependent glia activation. However, additional studies will be
necessary to further characterize this aspect in vivo and to assess
any contribution of endogenous dynorphin to the neuropathic
symptoms triggered by oxaliplatin administration. Nonetheless,
LOR17 effectiveness in reducing chemotherapy-induced thermal
hypersensitivity may be clinically relevant, considering that
oxaliplatin is a widely used anticancer drug and its
neurotoxicity is long-lasting (Tofthagen et al., 2013) and
represents one of its major dose-limiting side effects
(Kannarkat et al., 2007).
To characterize any unwanted effect elicited by LOR17 on
motor coordination, locomotor, and exploratory activity and
mood, specific behavioral tests were carried out by comparing
vehicle to 10 mg/kg LOR17; this dose was selected as it is the
lowest dose at which we observed the maximal reduction in
oxaliplatin-induced thermal hypersensitivity.
LOR17 (10 mg/kg) does not significantly alter motor
coordination, locomotor and exploratory activities and does
not cause pro-depressant-like effects. Conversely, U50,488 (10
mg/kg) significantly reduced rotarod performance and decreased
the mobility time in the forced-swim test. These findings are in
agreement with previous data showing that 10 mg/kg U50,488
(Ehrich et al., 2015) or 10 mg/kg U69,593 (Mague et al., 2003)
significantly reduced locomotor activity compared to vehicle. It
has been reported that U69,593 (0.1–10 mg/kg) dose-
dependently induces pro-depressant-like behaviors (Mague
et al., 2003) and 1 mg/kg U69,593 significantly decreases
novelty-induced locomotion and determines anhedonia-like
effects (White et al., 2015). Thus, providing further support for
the LOR17 advantageous pharmacological profile. Furthermore,
the fact that LOR17 could block in vitro ßarrestin-mediated
effects of U50488, is suggestive that this new KOPr agonist may
be able to counteract as well U50,488-induced effects on rotarod
performance and forced-swim behaviors. Further studies will be
carried out to assess whether, and to what extent, LOR17 is able
to counteract b arrestin-dependent effects induced by U50,488 in
vivo; if confirmed, this functional antagonism will add further
value to the favorable pharmacological profile displayed
by LOR17.
Given that LOR17 is a peptide, the above mentioned favorable
profile could be also related to a reduced distribution to the
central nervous system. It has been reported, in fact, that
activation of peripheral KOPr by D-amino acid peptide
agonists determined a significant antinociception in the
writhing test in mice, at doses lower than those required to
alter rotarod performance in the same animals (Vanderah et al.,
2008); moreover, these peptide agonists determined a significant
antinociception in the warm water tail withdrawal test only when
administered at doses higher than those that were effective in the
writhing test (Vanderah et al., 2008). Thus, further confirming
that the peptide agonists reported in the above mentioned study
were mainly peripherally active (the tail withdrawal test wasFrontiers in Pharmacology | www.frontiersin.org 20included as an experimental paradigm for centrally-mediated
antinociception) (Vanderah et al., 2008). Notably, we show that
LOR17 determine a significant antinociception both in the acetic
acid-inducedwrithing assay and in the warmwater tail-withdrawal
assay, when administered in the same range of doses. Thus,
suggesting that LOR17 may distribute to the central nervous
system. Furthermore, in the study mentioned above, Vanderah
and colleagues employed the ratio between potency in tail
immersion test and potency in writhing test as peripheral
selectivity index: according to this analysis, enadoline (brain
penetrating KOPr peptide agonist) and asimadoline (peripherally
selective KOPr peptide agonist) displayed a peripheral selectivity
indexequal to4 and13, respectively,whereas the innovativepeptide
agonists described in that study showed peripheral selectivity
indexes equal to 242 and 1429 (Vanderah et al., 2008). By
applying the same analysis to U50,488 and LOR17 potencies in
tail immersion and writhing assays, a peripheral selectivity index of
1.2 for U50,488 and 1.75 for LOR17 can be determined. These
findings further support that LOR17 may distribute to the central
nervous system. Nonetheless, further studies will be carried out to
fully characterize LOR17 pharmacokinetics.
To conclude, we believe that the findings reported in this
study set a sound foundation to support that KOPr selective
agonist LOR17 may be a useful research tool to further
characterize the functional selectivity of KOPr agonists, both in
vitro and in vivo, and might represent interesting lead compound
to develop more effective and safer analgesics. Future studies
aimed at expanding LOR17 in vivo characterization by means of
multiple experimental paradigms and different species will be
necessary, however, to fully confirm its selectivity to KOPr in
vivo and to assess to what extent the noteworthy premises
observed here will be fulfilled.DATA AVAILABILITY STATEMENT
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